Research group - Ali Mirazimi
In our research programmes, we will examine the molecular pathogenesis mechanism of haemorrhagic fever diseases such as Crimean Congo haemorrhagic fever Virus (CCHFV) and Ebola Disease Virus (EBOV).
Increased mobility in the general population and recent climate changes affecting the geographical distribution of viral vectors, combined with animal trade, immigrations and augmented bioterrorism threats, have heightened the risk of emerging viral diseases in Europe. These changing factors highlight the need for understanding the interactions between virus-vector-animal-human in the infection cycle and for the development of new countermeasures such as antivirals and vaccines. Knowledge regarding the pathogenesis of highly emerging viruses such as Viral Hemorrhagic Fever (VHF) is very limited and in some cases completely lacking. VHF diseases are caused by a diverse set of pathogens belonging to different virus families. Some of these viruses cause very severe diseases, with fatal outcomes.
It is obvious that the knowledge of virus biology, pathogenesis, vaccine development and therapeutics is highly limited for these important bio-threat. To achieve a globally effective health programme for this disease, there is a need for synergised national and international programmes with the capability to perform modern and advanced research. Our projects are focused on multinational/institutional collaboration. The major focus of our projects are i) understanding of the role of innate immune response to molecular pathogenesis of these diseases, ii) to understand Virus-Host cell interaction (animal, insects and human cells), iii) developing vaccines against emerging viral diseases, iv) developing new therapeutic tools against emerging viral diseases and v). Developing new diagnostic tools.
Research group leader
- Swedish research Council, 2016-2018
- Formas, 2016-2019
- European Commission. H2020, 2017-2023
- Initiative medicine innovation funds, 2015-2018
- Swedish foundation for Strategic Research, 2017-2021
- The Swedish foundation for International cooperation in research and higher education, 2015-2018
Professor Friedemann Weber, Germany (Vaccine development and molecular pathogenesis)
Professor Josef Penninger, Austria (Virus-host interaction)
Professor Thomas Helleday, Scilifelab, KI (Antiviral development)
Professor Heinrich Feldmann, NIAID, NIH, (Vaccine development and molecular pathogenesis)
Professor Yee-Joo Tan, Singapore (Molecular pathogenesis)
Professor Martin Groushop, Germany, (Vaccine development)
Professor, Matti Sällberg, LABMED, KI, (Vaccine development)
Professor Nazif Elaldi, Turkey, (Vaccine development)
Professor Anna Papa, Greece, (Virus epidemiology and Diagnostic)
Professor Ola Blixt, Copenhagen (Diagnostic)
Professor. Amadou Sall, Pasture Dakar, (Diagnostic)
Professor. Noel Tordo, Pasture Guinea (Epidemiology and diagnostic)
Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
J. Virol. 2017 May;91(10):
The Non-structural Protein of Crimean-Congo Hemorrhagic Fever Virus Disrupts the Mitochondrial Membrane Potential and Induces Apoptosis.
J. Biol. Chem. 2016 Jan;291(2):582-92
Crimean-Congo haemorrhagic fever replication interplays with regulation mechanisms of apoptosis.
J. Gen. Virol. 2015 Mar;96(Pt 3):538-46
Structure of Crimean-Congo hemorrhagic fever virus nucleoprotein: superhelical homo-oligomers and the role of caspase-3 cleavage.
J. Virol. 2012 Nov;86(22):12294-303
Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis.
Cytokine Growth Factor Rev. ;19(5-6):395-404
Crimean-Congo hemorrhagic fever virus activates endothelial cells.
J. Virol. 2011 Aug;85(15):7766-74
Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice.
J. Gen. Virol. 2010 Jun;91(Pt 6):1473-7
Production, purification and immunogenicity of recombinant Ebola virus proteins - A comparison of Freund's adjuvant and adjuvant system 03.
J. Virol. Methods 2017 04;242():35-45
Ebola virus disease: societal challenges and new treatments.
J. Intern. Med. 2015 Sep;278(3):227-37
Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process.
Pathog Dis 2015 Jul;73(5):
An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses.
J. Virol. 2010 Aug;84(16):8275-86
Amino acids 15-28 in the ectodomain of SARS coronavirus 3a protein induces neutralizing antibodies.
FEBS Lett. 2006 Jul;580(16):3799-803